Want to see UTMD full AI Analyst Report?
Top Page
Utah Medical Products
(NASDAQ:UTMD)
Select Model
Select Model
Rating:73Outperform
Price Target:
$72.00
▲(7.24% Upside)
Action:Reiterated
Date:07/24/26
UTMD’s score is driven primarily by strong financial quality—especially a near-zero leverage balance sheet and reliable cash generation—tempered by sustained revenue decline and softening cash flow versus prior years. Technicals are mixed with near-term weakness below key moving averages, while valuation is reasonable with a modest dividend yield. A recent shareholder vote outcome is supportive but not a major fundamental driver.
Positive Factors
Conservative Balance Sheet
Utah Medical's near-zero leverage and very small trailing debt provide durable financial flexibility. Low leverage reduces solvency risk during procedure-volume downturns, supports consistent capital allocation choices (operating investment, dividends or opportunistic M&A), and underpins resilience across a multi-month to multi-year horizon.
Negative Factors
Sustained Revenue Decline
Multi-year top-line contraction is a persistent structural headwind: declining revenue erodes operating leverage, can compress future growth opportunities, and raises the bar for management to restore momentum. If demand in core obstetrics/gynecology and neonatal segments remains weak, recovery may require new product wins or market expansion.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative Balance Sheet
Utah Medical's near-zero leverage and very small trailing debt provide durable financial flexibility. Low leverage reduces solvency risk during procedure-volume downturns, supports consistent capital allocation choices (operating investment, dividends or opportunistic M&A), and underpins resilience across a multi-month to multi-year horizon.
Read all positive factors
Utah Medical Products (UTMD) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$224.54M
Dividend Yield1.75%
Average Volume (3M)15.88K
Price to Earnings (P/E)21.9
Beta (1Y)0.53
Revenue Growth-7.00%
EPS GrowthN/A
CountryUS
Employees155
SectorHealthcare
Sector Strength45
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)3.22
Shares Outstanding3,184,025
10 Day Avg. Volume20,525
30 Day Avg. Volume15,884
Financial Highlights & Ratios
PEG Ratio-1.18
Price to Book (P/B)1.55
Price to Sales (P/S)4.81
P/FCF Ratio12.93
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Utah Medical Products Business Overview & Revenue Model
Company Description
Utah Medical Products, Inc. (UTMD) is a healthcare technology company focused on the creation, production, and supply of medical devices for the healthcare sector. UTMD offers a comprehensive portfolio of medical devices primarily serving labor an...
How the Company Makes Money
UTMD makes money by selling medical devices and related components to healthcare customers, generating revenue largely from product sales rather than services. A core driver is recurring demand for single-use/disposable products used in routine ho...
Utah Medical Products Financial Statement Overview
Summary
Income Statement
72
Positive
Balance Sheet
95
Very Positive
Cash Flow
84
Very Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 36.11M | 38.52M | 40.90M | 50.22M | 52.28M | 49.05M |
| Gross Profit | 19.82M | 19.88M | 24.14M | 30.04M | 32.20M | 30.92M |
| EBITDA | 14.67M | 17.06M | 19.57M | 24.75M | 27.74M | 26.34M |
| Net Income | 10.49M | 11.29M | 13.87M | 16.64M | 16.47M | 14.79M |
Balance Sheet | ||||||
| Total Assets | 124.57M | 122.54M | 122.54M | 135.46M | 123.87M | 115.64M |
| Cash, Cash Equivalents and Short-Term Investments | 87.53M | 85.76M | 82.98M | 92.87M | 75.05M | 60.97M |
| Total Debt | 194.00K | 225.00K | 338.00K | 295.00K | 341.00K | 396.00K |
| Total Liabilities | 2.54M | 3.27M | 5.11M | 7.14M | 9.62M | 8.50M |
| Stockholders Equity | 122.03M | 119.27M | 117.43M | 128.31M | 114.25M | 107.14M |
Cash Flow | ||||||
| Free Cash Flow | 10.20M | 14.32M | 14.60M | 21.64M | 20.33M | 20.65M |
| Operating Cash Flow | 10.46M | 14.69M | 14.83M | 22.28M | 21.15M | 21.20M |
| Investing Cash Flow | -266.00K | -371.00K | -208.00K | -639.00K | -818.00K | -552.00K |
| Financing Cash Flow | -4.73M | -12.34M | -23.84M | -4.17M | -5.48M | -10.90M |
Utah Medical Products Technical Analysis
Positive
67.14
Price Trends
68.31
Positive
66.55
Positive
62.80
Positive
Market Momentum
0.63
Negative
58.43
Neutral
69.58
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For UTMD, the sentiment is Positive. The current price of 67.14 is below the 20-day moving average (MA) of 69.34, below the 50-day MA of 68.31, and above the 200-day MA of 62.80, indicating a bullish trend. The MACD of 0.63 indicates Negative momentum. The RSI at 58.43 is Neutral, neither overbought nor oversold. The STOCH value of 69.58 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for UTMD.
Utah Medical Products Risk Analysis
Utah Medical Products disclosed 10 risk factors in its most recent earnings report. Utah Medical Products reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Utah Medical Products Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | $224.54M | 21.90 | 8.74% | 1.84% | -7.00% | ― | |
69 Neutral | $184.46M | 24.03 | 14.00% | ― | 3.50% | 157.81% | |
67 Neutral | $311.28M | -8.69 | -246.44% | ― | 17.41% | -189.91% | |
52 Neutral | $188.78M | -83.54 | -13.61% | ― | 23.30% | 57.37% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
UTMD
Utah Medical Products
72.75
17.02
30.55%
INFU
InfuSystem Holdings
9.22
3.15
51.89%
KRMD
REPRO-MED Systems
4.23
0.95
28.96%
SMTI
Sanara MedTech
34.00
9.48
38.66%
Utah Medical Products Corporate Events
Executive/Board ChangesShareholder Meetings
Utah Medical Shareholders Back Board, Auditor and Pay Policies
Positive
May 4, 2026
On May 1, 2026, Utah Medical Products stockholders voted on key governance and compensation matters at the company’s annual meeting, including the election of directors, ratification of the auditor, and an advisory say-on-pay resolution. Sha...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.